节点文献

加强对药物临床试验中人类遗传资源的管理

Strengthen the management of human genetic resources in drug clinical trials

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 王瓅珏吴明凤王丹蕾范华莹谢振伟张华王豪

【Author】 WANG Li-jue;WU Ming-feng;WANG Dan-lei;FAN Hua-ying;XIE Zhen-wei;ZHANG Hua;WANG Hao;Science and Research Department,Peking University People’s Hospital;

【机构】 北京大学人民医院科研处

【摘要】 人类遗传资源样本是国家生物安全的重要屏障。药物临床试验机构通常广泛参与国际合作的药物临床试验项目,并涉及人类遗传资源采集、收集、买卖、出口出境等关键环节的管理。按照法律法规的更新不断建立健全相关管理制度,逐步达到规范管理与促进合作的目标,对我国的新药临床试验会起到很大的促进作用。本文结合法规与制度,分析了本院药物临床试验机构近年来上报遗传资源申请的审批情况,初步探讨药物临床试验机构对人类遗传资源的管理。

【Abstract】 The management of human genetic resource is an important component of our national biosecurity.Drug clinical trial institutions widely participate in international cooperation of clinical trials and are involved in the collection,sales,export,etc. of human genetic resources. It’s very important to refine the management system in accordance with laws and regulations, and gradually achieve the objective of standardized management and deepened cooperation,which would play a significant role in promoting new drug clinical trials in China. The purpose of this research is to preliminarily discuss the management of human genetic resource in clinical trial institutions,through laws and regulations and the analysis of approved application of genetic resources from drug clinical trial institutions in our hospital.

【基金】 国家“重大新药创制”科技重大专项资助项目(012ZX09303019)
  • 【文献出处】 中国新药杂志 ,Chinese Journal of New Drugs , 编辑部邮箱 ,2018年11期
  • 【分类号】R969.4
  • 【被引频次】11
  • 【下载频次】528
节点文献中: 

本文链接的文献网络图示:

本文的引文网络